Publication date: Feb 09, 2025
The present study intended to characterize the profile of soluble immune mediators in serum samples and in the cerebrospinal fluid (CSF) microenvironment from parturients with acute and convalescent COVID-19 as compared to healthy controls (HC), during the circulation of B. 1.1. 28 and B. 1.1. 33 SARS-CoV-2 strains which were identified during the initial spread of COVID-19 in Brazil. Data demonstrated increased levels of immune mediators in serum at acute infection with a clear waning during convalescent COVID-19. Conversely, a progressive increase of immune mediators was observed in CSF from acute infection towards convalescent COVID-19. Immune mediator signatures and integrative correlation circuits further confirmed these findings and supported the existence of dichotomic microenvironments in serum and CSF compartments. While a waning of correlations involving pro-inflammatory cytokines with increased connectivity of regulatory cytokines were observed in serum samples from acute towards convalescent COVID-19, an increasing frequency of correlations mediated by pro-inflammatory cytokines with decreased connectivity of regulatory cytokine were the hallmark of CSF. Correlations analysis identified a set of molecules associated with the dichotomic crosstalk between serum and CSF compartments, including chemokines (CXCL8, CCL5, CXCL10) and regulatory cytokines (IL-4 and IL-9). These immune biomarkers may represent potential targets for therapeutic strategies in parturients with COVID-19. Together, these findings demonstrated the existence of a divergent landscape of soluble immune mediators in serum and CSF, emphasizing the relevance of understanding the systemic and compartmentalized immune response elicited by SARS-CoV-2 infection during pregnancy.
Concepts | Keywords |
---|---|
Biomarkers | cerebrospinal fluid |
Brazil | COVID-19 |
Covid | cytokines |
Healthy | immune mediators |
Serum | pregnancy |
SARS-CoV-2 |
Semantics
Type | Source | Name |
---|---|---|
disease | MESH | COVID-19 |
disease | IDO | acute infection |
drug | DRUGBANK | Binetrakin |
disease | IDO | immune response |
pathway | REACTOME | SARS-CoV-2 Infection |
disease | MESH | Long Covid |